Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

IQVIA Holdings Inc., EBITDA calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income attributable to IQVIA Holdings Inc. 1,091 966 279 191 259
Add: Net income attributable to noncontrolling interest 5 29 36 25
Add: Income tax expense 260 163 72 116 59
Earnings before tax (EBT) 1,351 1,134 380 343 343
Add: Interest expense 416 375 416 447 414
Earnings before interest and tax (EBIT) 1,767 1,509 796 790 757
Add: Depreciation and amortization 1,130 1,264 1,287 1,202 1,141
Earnings before interest, tax, depreciation and amortization (EBITDA) 2,897 2,773 2,083 1,992 1,898

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. IQVIA Holdings Inc. EBITDA increased from 2020 to 2021 and from 2021 to 2022.

Enterprise Value to EBITDA Ratio, Current

IQVIA Holdings Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 44,519
Earnings before interest, tax, depreciation and amortization (EBITDA) 2,897
Valuation Ratio
EV/EBITDA 15.37
Benchmarks
EV/EBITDA, Competitors1
AbbVie Inc. 19.98
Amgen Inc. 14.08
Bristol-Myers Squibb Co. 7.48
Danaher Corp. 24.13
Eli Lilly & Co. 86.09
Gilead Sciences Inc. 12.20
Johnson & Johnson 16.08
Merck & Co. Inc. 39.74
Moderna Inc.
Pfizer Inc. 21.01
Regeneron Pharmaceuticals Inc. 15.67
Thermo Fisher Scientific Inc. 20.24
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 14.02
EV/EBITDA, Industry
Health Care 14.38

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

IQVIA Holdings Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 53,832 55,061 47,884 42,823 38,267
Earnings before interest, tax, depreciation and amortization (EBITDA)2 2,897 2,773 2,083 1,992 1,898
Valuation Ratio
EV/EBITDA3 18.58 19.86 22.99 21.50 20.16
Benchmarks
EV/EBITDA, Competitors4
AbbVie Inc. 13.31 13.44 21.34 13.68
Amgen Inc. 12.97 13.22 12.24 12.26
Bristol-Myers Squibb Co. 9.46 8.65 34.35 23.84
Danaher Corp. 18.42 21.05 26.68 25.23
Eli Lilly & Co. 37.74 29.85 23.67 21.40
Gilead Sciences Inc. 13.89 8.57 24.90 11.77
Johnson & Johnson 14.78 14.47 18.20 16.28
Merck & Co. Inc. 13.91 12.18 16.05 13.66
Moderna Inc. 4.52 3.77
Pfizer Inc. 6.12 8.64 15.78 9.17
Regeneron Pharmaceuticals Inc. 15.27 6.68 12.70 14.80
Thermo Fisher Scientific Inc. 20.25 20.21 18.72 19.74
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 13.10 12.43 19.64 14.94
EV/EBITDA, Industry
Health Care 13.35 13.31 16.61 14.16

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 53,832 ÷ 2,897 = 18.58

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/EBITDA Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. IQVIA Holdings Inc. EV/EBITDA ratio decreased from 2020 to 2021 and from 2021 to 2022.